The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0544 ET - Novo Nordisk sees promise for its Wegovy weight-loss pill in the European market over the next 1-3 years, partly because of increased use of digital healthcare services, SB1 Markets analyst Johan Unnerus writes. Novo's Wegovy pill is now approved in the U.K., making it the first European market where the drug has been approved, Unnerus says. The U.K. launch is expected in the coming weeks, with a large part of the demand anticipated to come from private-paying patients, he adds. The market offers broad access via the NHS and digital healthcare solutions, but the criteria for publicly funded treatment are relatively strict. The bank also expects approval in the EU within 1-6 weeks. SB1 Markets reiterates its buy rating and 350 Danish kroner target price on the stock. Shares fall 0.1%. (dominic.chopping@wsj.com)
0509 ET - The outlook for Middle East medical tourism to Thailand is improving, after signs of a recovery in tourist arrivals and flight connectivity, DBS Group Research analysts say in a note. Visitors from the Middle East account for 18% of Thailand's medical-tourism revenue and remain a key growth market. Tourist arrivals from the region to Thailand picked up in May, compared with April and March. DBS notes that major Gulf carriers have largely restored flight frequencies, citing Flightradar24 data. "We believe the recovery in flight capacity is a leading indicator of future tourist arrivals and should support continued growth in [Middle East] visitor arrivals during [2H]," DBS says. (amanda.lee@wsj.com)
0324 ET - Bumrungrad Hospital is likely to benefit from resilient tourist arrivals from the Middle East in 2Q despite ongoing geopolitical tensions, says CGS International's Kasem Prunratanamala in a note. Travel demand from the region has started to stabilize despite the conflict, as May Mideast arrivals fell only 1.9% on year, he adds. This should bode well for the Thai hospital operator as revenue from Middle East patients grew 21% on year in 1Q, compared with a 1% gain in overall revenue, he says. Meanwhile, reduced Cambodian medical tourist numbers due to the Thailand-Cambodia border dispute could weigh on Bumrungrad's 2Q revenue, but he expects this drag to ease on favorable base effects. CGSI reiterates its add rating and 212.0 baht target price. Shares rise 0.85% to 177.0 baht. (megan.cheah@wsj.com)
2304 GMt - Forsyth Barr thinks the market is too bearish about the outlook for Summerset. The retirement-village operator's share price has fallen more than 30% to NZ$8.23 so far this year. Analyst Will Twiss says this reflects growing investor concerns around issues including the cash-generation potential of Summerset's existing villages and the strength of its balance sheet. "These concerns are not unfounded," says Forsyth Barr. "However, we believe the market has become excessively pessimistic." It thinks investors are assuming a higher probability of balance-sheet stress than is justified. They're also assuming a steady-state cash return on net tangible assets of only 3% from Summerset's existing villages and little to no value creation from its development engine, Forsyth Barr says. It retains an outperform call and NZ$12.60/share price target. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 12, 2026 12:20 ET (16:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments